Last reviewed · How we verify

London North West Healthcare NHS Trust — Portfolio Competitive Intelligence Brief

London North West Healthcare NHS Trust pipeline: 3 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tagitol V, Lo So, Readi-Cat 2 Tagitol V, Lo So, Readi-Cat 2 marketed
Diamorphine or Morphine Diamorphine or Morphine marketed Opioid agonist Mu opioid receptor (OPRM1) Pain management
oestradiol oestradiol marketed Other
Citramag powder Citramag powder phase 3 Osmotic laxative Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aboca Spa Societa' Agricola · 1 shared drug class
  2. Ahmed M Maged, MD · 1 shared drug class
  3. Ain Shams University · 1 shared drug class
  4. Amsterdam UMC, location VUmc · 1 shared drug class
  5. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  6. Azienda Policlinico Umberto I · 1 shared drug class
  7. Bayer · 1 shared drug class
  8. Aarhus University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for London North West Healthcare NHS Trust:

Cite this brief

Drug Landscape (2026). London North West Healthcare NHS Trust — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/london-north-west-healthcare-nhs-trust. Accessed 2026-05-17.

Related